ADIL Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc. (ADIL) is expected to report earnings on November 13, 2026, before the market open. The stock has had a Post-Earnings Announcement Drift (PEAD) of -3.2% since its last earnings release on August 14, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.
Sector
Healthcare
Industry
Biotechnology